Chugai Pharmaceutical has reported a new humanized antibody (Ab, SOF-10) that targets latent TGF-β1 and selectively blocks protease- and integrin αVβ8-mediated latent TGF-β1 activation.

At the ongoing AACR Immuno-Oncology Conference (AACR IO) in Los Angeles, Ampersand Biomedicines Inc. gave a presentation on promising results in the field regarding AMP-410, an anti-VEGF/4-1BB antibody construct that limits 4-1BB activation in VEGF-rich tumor types, thus achieving durable efficacy.

SLAMF6 is an immune cell receptor whose function was not clear. Does it activate or inhibit cells? The results so far have been contradictory. Now, scientists at the Institut de Recherches Cliniques de Montréal have unveiled evidence that SLAMF6, a protein of the SLAM family that binds to copies of itself, is regulated by interactions between molecules of the same receptor within the same cell.